About: Galunisertib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020. Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.

Property	Value
dbo:abstract	Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020. Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition. (en)
dbo:casNumber	700874-72-2
dbo:chEBI	137064
dbo:fdaUniiCode	3OKH1W5LZE
dbo:kegg	D10437
dbo:pubchem	10090485
dbo:thumbnail	wiki-commons:Special:FilePath/Galunisertib.svg?width=300
dbo:wikiPageID	52831864 (xsd:integer)
dbo:wikiPageLength	3384 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	974805155 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Eli_Lilly dbr:TGF-b dbc:Experimental_cancer_drugs dbr:Hepatocellular_carcinoma dbr:PD-L1
dbp:c	22 (xsd:integer)
dbp:casNumber	700874 (xsd:integer)
dbp:chebi	137064 (xsd:integer)
dbp:chemspiderid	8266022 (xsd:integer)
dbp:h	19 (xsd:integer)
dbp:iupacName	4 (xsd:integer)
dbp:kegg	D10437 (en)
dbp:n	5 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:pubchem	10090485 (xsd:integer)
dbp:routesOfAdministration	PO (en)
dbp:smiles	N1=CC=CC1=C2NCCC2 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	IVRXNBXKWIJUQB-UHFFFAOYSA-N (en)
dbp:unii	3 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:Fdacite
dcterms:subject	dbc:Experimental_cancer_drugs
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020. Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition. (en)
rdfs:label	Galunisertib (en)
owl:sameAs	yago-res:Galunisertib wikidata:Galunisertib https://global.dbpedia.org/id/2Y36k
prov:wasDerivedFrom	wikipedia-en:Galunisertib?oldid=974805155&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Galunisertib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Galunisertib
is dbo:wikiPageRedirects of	dbr:C22H19N5O
is dbo:wikiPageWikiLink of	dbr:Epithelial–mesenchymal_transition dbr:LY-2109761 dbr:C22H19N5O dbr:GW-788,388 dbr:TGF_beta_receptor_1 dbr:Transforming_growth_factor_beta
is foaf:primaryTopic of	wikipedia-en:Galunisertib